Arrhythmias & electrophysiologyCohort study
Impact of weight/body mass index (BMI) on clinical and bleeding events in 26 805 atrial fibrillation patients on edoxaban from the Global ETNA-AF Registry
- Prospective registry cohort study
- multinational registry
- Europe and Asia
Authors' conclusion
In a large cohort of AF patients, U-shaped relationships were found between body weight/BMI and all-cause/CV death at 2-year follow-up.
Study context
- Population
- Atrial fibrillation (AF) patients receiving edoxaban in Europe and Asia (Global ETNA-AF)
- Participants
- 26,805 patients
- Exposure
- Body weight/BMI categories
- Outcome
- Clinical/bleeding event rates by body weight/BMI
- Follow-up
- 2 years
Main finding
As reported in the abstract
Body weight/BMI and clinical/bleeding events
- Body weight (mean ± SD)
- 72.2 ± 18.1 kg
- BMI (mean ± SD)
- 26.4 ± 5.0 kg/m²
- Higher-risk cut-off, any stroke/SEE
- BMI ≤20 kg/m²
- Higher-risk cut-off, haemorrhagic stroke
- BMI ≤20 kg/m², weight ≤53 kg
- Higher-risk cut-off, cardiovascular (CV) death
- BMI ≤22 and ≥32 kg/m², weight ≤62 kg
- Higher-risk cut-off, all-cause death
- BMI ≤24 and ≥30 kg/m², weight ≤69 kg and ≥118 kg
Observational data: associations, not effects.
Original publication
Impact of weight/BMI on clinical and bleeding events in 26 805 atrial fibrillation patients on edoxaban from the Global ETNA-AF Registry. Eur J Prev Cardiol. Published 25 October 2025. doi:10.1093/eurjpc/zwaf685
Summarised from the published abstract; every number is checked against it